Blog

Early Data for bluebird bio Gene-Therapy Candidate Show Some Promise – Genetic Engineering & Biotechnology News


STAT

Early Data for bluebird bio GeneTherapy Candidate Show Some Promise
Genetic Engineering & Biotechnology News
bluebird bio today disclosed its first data, including some promising results, from a pair of clinical studies assessing its LentiGlobin™ gene therapy candidate—including a Phase III study that followed a change in its manufacturing process. In the
Bluebird Bio's gene therapy for blood disorders yields some impressive results ― but also raises questionsSTAT


Bluebird Reports Early Results From Upgraded Gene TherapyXconomy
Bluebird bio steps up with a promising snapshot of its gene therapy upgradeEndpoints News
FierceBiotech –Business Wire (press release) –StreetInsider.com
all 10 news articles »

2017-06-23 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.